xFusion Unveils Breakthrough High-Performance Computing Innovations at ISC 2025
13.6.2025 05:33:00 CEST | Business Wire | Press Release
xFusion International Pte. Ltd (xFusion) showcased its latest advancements in high-performance computing (HPC) and sustainable intelligent computing solutions at the International Supercomputing Conference (ISC) 2025, held from June 10 to 13 in Hamburg, Germany. As a global leader in HPC and computing infrastructure, xFusion highlighted its commitment to empowering industries and institutions with cutting-edge technologies that accelerate innovation and digital transformation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612879566/en/
Arthur Wang
Revolutionizing Computing with Innovative Solutions
At the Vendor Roadmap Session on June 12, Arthur Wang, Director of xFusion Computing Solution, delivered a compelling keynote titled "Innovative Computing with xFusion." Arthur emphasized the increasing demand for computing power in the age of AI and intelligent agents, as well as xFusion’s role in addressing these challenges.
"The rise of intelligent agents has triggered an explosive demand for computing power. At xFusion, we are tackling this challenge head-on by pioneering advancements in HPC and intelligent computing technologies. From our FusionServer V8 series to our FusionPoD liquid-cooled cabinets, we are providing sustainable, efficient, and high-performance solutions to empower industries and institutions globally," said Arthur Wang.
Pioneering Green and Sustainable Data Centers
At exhibition booth, xFusion is demonstrating the deep integration of its computing technology with industry applications, drawing significant attention from attendees. To support the green and sustainable development of its customers' businesses, xFusion is leading the way with its FusionPoD rack-scale server. Designed for efficiency and energy savings, this system features an open architecture compatible with diverse computing power. Key features include:
- High-Density: Supports up to 144 CPUs per cabinet.
- Intelligent O&M: A tri-bus design for power, network, and liquid enables blind mating, improving O&M efficiency and supporting future robotic, unmanned operations.
- 100% Liquid Cooling: A native cold-plate liquid-cooling design, paired with a passive water-cooled rear door, achieves a pPUE as low as 1.06 and has earned the world's first TÜV SÜD certification for this technology.
Recently, xFusion partnered with Global Switch to rapidly deploy a liquid-cooled node at its Hong Kong data center, meeting stringent low-carbon requirements while delivering significant cost and efficiency benefits to the customer.
Accelerating HPC Application and Digital Transformation
The FusionOne HPC solution provides a viable path for industries such as scientific research and manufacturing simulation. Through deep hardware-software integration, the solution has been successfully deployed at institutions like the Poznan Supercomputing and Networking Center (PSNC), Istanbul Technical University, and Technische Universität Ilmenau to meet their growing research and educational demands.
To further accelerate enterprise digital transformation, xFusion offers:
- FusionOne DFS (Distributed File System): A high-performance storage solution delivers unparalleled throughput, scalability, and efficiency for modern workloads. With up to 220GB/s read bandwidth, 125GB/s write bandwidth, and 5,700K IOPS, it handles massive workloads effortlessly. FusionOne DFS achieves 94.1% EC utilization, offering flexibility and reliability for the AI and HPC era.
- FusionOne AI: A solution accelerates AI application deployment by combining computing, model, and application into a seamless, one-stop platform. Featuring open integration with third-party AI tools like LLaMA and Hugging Face, it simplifies GenAI deployment. Achieve 35% higher computing utilization with innovative GPU virtualization, including 1% GPU slicing for precise resource allocation. Built for scalability, FusionOne AI supports diverse workloads, from edge to cluster environments, ensuring smooth evolution and compatibility with mainstream CPUs and GPUs.
Driving the Era of Intelligent Computing
As the era of intelligent agents dawns, AI is fundamentally reshaping computing infrastructure. xFusion is seizing this opportunity to innovate on foundational technologies, collaborate with global partners, and accelerate the application of high-performance computing across all industries, ensuring that intelligent computing and digital energy can better serve everyone.
"At xFusion, we believe in combining cutting-edge technology with sustainability to create a smarter, more efficient future. Our three consecutive year participation at ISC 2025 underscores our commitment to driving the evolution of HPC and AI. In the future, xFusion will continue to innovate with partners through our xLAB, reshaping infrastructure to help enterprises in their digital and intelligent transformation and unlock the true value of computing," said Arthur Wang.
About xFusion
xFusion International Pte. Ltd. is a leading global provider of computing infrastructure and services. Driven by the vision "Let Computing Serve You Better," xFusion focuses on creating value for its customers and partners, accelerating digital transformation across a wide range of industries. Headquartered in Singapore, xFusion has a substantial global presence, including 9 research centers, 7 regional offices, and 6 Global Technical Assistance Centers (GTACs). xFusion's commitment to providing innovative computing solutions has enabled it to serve over 10,000 customers in more than 100 countries and regions, including the telecom, finance, internet, transportation, and energy sectors.
Official site: https://www.xfusion.com/en
Case Center: https://www.xfusion.com/static/en/cases
LinkedIn/X/Facbook/Youtube: xFusion Global
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612879566/en/
Contacts
information@xfusion.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom